Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. (Q45050594)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Paweł Wiczling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Bart Keymeulen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Herman Waldmann

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

Geoff Hale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Evy Vandemeulebroucke

7

object named as

Evy Vandemeulebroucke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Peppy Rebello

2

object named as

Peppy Rebello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

William J Jusko

6

object named as

William J Jusko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Emma Bolam

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Annette-G Ziegler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lucienne Chatenoud

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Chantal Mathieu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

10 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Pharmacology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1238-1248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

CD3-specific antibody-induced active tolerance: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

Pharmacokinetics of CAMPATH-1H: assay development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009356299

21 January 2018

Identifiers

DOI

10.1177/0091270009356299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147616%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference